Key Points
- Director Deborah Autor sold 34,819 Amneal Pharmaceuticals shares on May 11 at an average price of $12.94, totaling about $450,558. After the sale, she still held 93,660 shares, reducing her stake by 27.10%.
- Amneal recently reported quarterly EPS of $0.27 on revenue of $722.52 million. Analysts currently expect the company to earn 0.92 EPS for the full year.
- Wall Street sentiment is cautiously positive, with seven analysts rating AMRX a Buy and one a Hold. The consensus price target is $15.00, above the stock’s recent opening price of $12.60.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director Deborah Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Amneal Pharmaceuticals Price Performance
AMRX opened at $12.60 on Wednesday. The business's 50-day moving average is $12.73 and its two-hundred day moving average is $12.79. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.02 and a 1 year high of $15.42. The firm has a market capitalization of $3.96 billion, a PE ratio of 33.16 and a beta of 1.32.
Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million for the quarter. As a group, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.
Institutional Trading of Amneal Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Amneal Pharmaceuticals by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company's stock worth $179,729,000 after acquiring an additional 403,582 shares during the last quarter. Rubric Capital Management LP increased its stake in shares of Amneal Pharmaceuticals by 5.3% in the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company's stock worth $123,473,000 after acquiring an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Amneal Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company's stock worth $70,723,000 after acquiring an additional 81,546 shares during the last quarter. Morgan Stanley increased its stake in shares of Amneal Pharmaceuticals by 37.5% in the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company's stock worth $60,708,000 after acquiring an additional 1,315,018 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its stake in shares of Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company's stock worth $35,333,000 after acquiring an additional 558,877 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
AMRX has been the topic of a number of research analyst reports. UBS Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a "buy" rating and a $19.00 price target on the stock. Weiss Ratings upgraded Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday. Zacks Research lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 6th. Finally, Truist Financial upped their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $15.00.
Read Our Latest Research Report on AMRX
About Amneal Pharmaceuticals
(
Get Free Report)
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
